Tiziana Life SciencesTLSA
About: Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
Employees: 9
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
33% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 9
10% more funds holding
Funds holding: 30 [Q3] → 33 (+3) [Q4]
0.98% less ownership
Funds ownership: 1.88% [Q3] → 0.91% (-0.98%) [Q4]
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
61% less capital invested
Capital invested by funds: $1.78M [Q3] → $698K (-$1.08M) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for TLSA.
Financial journalist opinion
Based on 4 articles about TLSA published over the past 30 days









